Public and private immunization programs perform a critical role in vaccine safety by ensuring that their providers report suspected adverse events following vaccination through VAERS. Because VAERS is a passive surveillance system, there may be underreporting or biased reporting. Furthermore, VAERS usually cannot determine if an adverse event was actually caused by a vaccine. By collating and analyzing VAERS data nationwide, FDA and CDC are able to identify and respond to vaccine-associated risks potentially not identified in pre-licensure assessments. In addition, VAERS can detect unusual increases in recognized events, vaccine lots with unusual numbers or types of reported events, and, by collecting and following up additional case information, may detect pre-existing conditions that may be contraindications to vaccination. Results of VAERS analyses are used to trigger investigations of hypothesized relationships between a vaccine and adverse events.
VAERS data are available via the VAERS website (http://www.vaers.hhs.gov). Routine updates and/or custom searches are available to grantees on request from the VAERS program. Adverse events designated as "serious" require additional follow-up by the VAERS program to obtain more complete medical information with which to evaluate the case. These and other enhancements to CDC's vaccine safety efforts will add to the knowledge regarding vaccine safety and help maintain confidence in our vaccination programs.
Currently the NCVIA specifies vaccines/toxoids and types of events that must be reported. However, healthcare providers are encouraged to report all clinically significant events to VAERS. Reporting forms and instructions are available from the VAERS website (http://www.vaers.hhs.gov) or by calling 1-800-822-7967 or sending an e-mail to info@vaers.org. To modernize and enhance public health surveillance and information systems, CDC and its public health partners are implementing the National Electronic Disease Surveillance System (NEDSS). NEDSS implementation strategies include ensuring that the relevant activities of state and local immunization programs are consistent with the functional and technical specifications of the NEDSS information architecture. State and local immunization programs should evaluate current activities with respect to the NEDSS information system architecture and modify these activities, if necessary, so that they are consistent with NEDSS specifications. Information describing these specifications can be found on the internet at http://www.cdc.gov/nedss/BaseSystem/NEDSSRequirements.pdf.
• 9.1e. Ensure that health department staff responsible for VPD surveillance and response is trained to perform VPD case and suspect case investigations, outbreak investigations, and outbreak control.
9.1f. Initiate VPD case investigations and outbreak investigations promptly and implement outbreak control measures and other necessary public health interventions in a timely manner.
9.1g. Develop and distribute written up-to-date laboratory guidelines for each VPD detailing the appropriate clinical specimens for testing, the recommended laboratory tests and laboratories, appropriate specimen handling, and expected timelines for laboratory results. Ensure that laboratory capacity is available for testing clinical specimens for VPDs.
9.1h. Ensure that clinics, schools, child care facilities, hospitals and other VPD reporting sites routinely submit surveillance reports to health departments.
9.1i. Conduct enhanced, active surveillance in communities where a VPD is prevalent, or where there is increased incidence.
9.1j. Pursue unreported cases of VPDs by searching laboratory, hospital and/or death certificate data, especially for VPDs which are rare or uncommon.
9.1k. Investigate outbreaks occurring in schools, child care and institutional facilities, and offer control efforts either through provision of vaccine in public clinics or by referrals to primary healthcare providers. In outbreak settings, obtain clinical specimens from at least one case for laboratory confirmation. Performance measure: Grantee is in compliance with NHIN standards.
Electronic Data Submission to CDC
Recommended objectives 9.2c. Assure that laboratories report all results which indicate need for public health action, as described in CDC's "Manual for Surveillance of Vaccine-Preventable Diseases."
9.2d. Ensure that appropriate procedures exist and are followed for entering, analyzing, and reporting surveillance, investigation and outbreak data in a timely fashion.
9.2e. Analyze, review, and interpret surveillance data regularly and outbreak data as needed.
9.2f. Disseminate surveillance morbidity and mortality data regularly to surveillance partners, network participants, providers, policy makers, and the public. 
Required objectives
Quality of VPD surveillance 9.3a. Haemophilus influenzae: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of Haemophilus influenzae invasive disease cases among children <5 years of age with complete vaccination history 9.3b. Haemophilus influenzae: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of Haemophilus influenzae isolates from cases <5 years of age that were serotyped 9.3c. Measles: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of measles cases with complete vaccination history 9.3d. Measles: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of measles cases or chains of transmission that have an imported source 9.3e. Meningococcal disease: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of cases with complete vaccination history 9.3f. Meningococcal disease: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of meningococcal cases with known serogroup 9.3g. Mumps: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of mumps cases for which appropriate clinical specimens were obtained and submitted to the laboratory 9.3h. Mumps: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of cases with complete vaccination history 9.3i. Pertussis: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of cases from which clinical specimens are obtained 9.3j. Pertussis: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of probable and confirmed pertussis cases meeting the clinical case definition that is laboratory confirmed 9.3k. Pertussis: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of cases confirmed by isolation of B. pertussis by culture 9.3l. Pertussis: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of probable and confirmed pertussis cases with a complete vaccination history 9.3m. Pneumococcal invasive disease: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of pneumococcal invasive disease cases among children <5 years of age with complete vaccination history 9.3n. Pneumococcal invasive disease: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of pneumococcal isolates from cases of invasive disease <5 years of age that are serotyped and tested for antibiotic resistance 9.3o. Rubella: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of confirmed rubella cases among women of child-bearing age with known pregnancy status 9.3p. Rubella: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: The proportion of confirmed rubella cases that are laboratory confirmed 9.3q. Varicella: Monitor the quality of VPD surveillance by reviewing surveillance data and surveillance indicators to identify problems and strategies to resolve the problems.
Performance measure: Percentage of cases with complete information for age, vaccination history, and severity of disease Required objectives VAERS reporting 9.4a. Ensure at least one employee is designated with overall responsibility for vaccine safety and VAERS reporting. Duties should include completing VAERS reports electronically and/or in hard copy form, promptly reviewing all VAERS reports received, submitting reports to VAERS contractor within 7 days of receipt, requesting, collecting and forwarding supplemental medical information, answering provider and parent inquiries regarding VAERS and vaccine safety, and coordinating communication with and from media. Use state and local policies and procedures for VAERS reporting.
Performance measure: Name of person with overall responsibility for vaccine safety and VAERS reporting Local VAERS 9.4b. Ensure all local health departments and public health clinics know how to report and do report adverse events to the grantee using the VAERS form and/or secure webbased reporting.
Performance measure: Date by which communication will occur Recommended objectives 9.4c. Establish/maintain protocols and systems to accept reports of adverse events following immunization; VAERS reports may be submitted by public and private healthcare providers, parents, vaccinees, and other concerned individuals.
Performance measure: Increase the number of adverse events reported to the immunization program office (by vaccine type and reporting source) and increase the timeliness of reporting (measured by date of report minus date of symptom onset) 9.4d. Provide all immunization providers (public and private) with a copy of state policies on VAERS reporting, copies of the VAERS reporting form, instructions on which adverse events must be reported and which can be reported, instructions on completing and submitting the form, and updates on VAERS reporting as they arise.
Performance measure: Number of immunization service providers (e.g., pediatricians, family practitioners, general practitioners, clinics) receiving initial VAERS and other safety information and training 9.4e. Encourage providers to voluntarily submit VAERS reports on adverse events not listed in the National Vaccine Injury Table. 9.4f. Communicate information on vaccine safety in a timely way to all healthcare providers, public health officials, state professional associations, and the public, using tools including media interviews, press releases, information kits, etc.
9.5 Follow up on all reports of serious adverse events received by the state agency (e.g., death, life-threatening illness, hospitalization and permanent disability) following immunization.
Supplemental information 9.5a. Submit supplemental medical information requested by the national VAERS program within 10 working days of receipt of request.
Performance measure: Percentage of requested supplemental reports submitted within 10 working days of receipt of request Recommended objectives 9.5b. Review all VAERS reports that are sent to the state agency upon receipt; verify accuracy of key information designated with "boxes" on form, attempt to complete critical fields, and assign an immunization project number. If all critical information cannot be obtained by the grantee, the report should be forwarded to VAERS if it contains at least the following: a patient identifier (nominal or non-nominal); a vaccine; an adverse event description; and an identifiable reporter (of the adverse event).
Performance measure: Percentage of VAERS reports submitted to the contractor within 5 working days of receipt
Additional Objectives
Recommended objectives 9.6a. Collaborate with local/state influenza surveillance coordinators to ensure adequate local and state influenza surveillance, including virologic surveillance and outpatient surveillance for influenza-like illness. Develop plans for timely and coordinated dissemination of influenza vaccination promotions. Ensure that state and local influenza virus surveillance data are disseminated to providers and the public during each influenza season.
9.6b. Assure prenatal screening of all pregnant women for rubella antibody and documentation of results in provider and birthing hospital chart.
Performance measure: Number and percent of pregnant women with documentation of rubella status in pre-delivery hospital record 9.6c. Assure rubella antibody-negative mothers are made aware of benefits and risks of rubella vaccine, offered rubella vaccine following delivery, and acceptors receive the vaccine before hospital discharge.
Performance measure: Number and percent of rubella antibody-negative pregnant women receiving rubella vaccine following delivery and prior to discharge 9.6d. Maintain a registry of persons with HBsAg-positive results.
This document can be found on the cdc website at: http://www.cdc.gov/vaccines/vac-gen/policies/ipom/downloads/chp-09-epi-surv.pdf
